Fischel JL - Search Results

1

Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer.

Magné N, Fischel JL, Dubreuil A, Formento P, Marcié S, Lagrange JL, Milano G. Magné N, et al. Among authors: fischel jl. Br J Cancer. 2002 Mar 4;86(5):819-27. doi: 10.1038/sj.bjc.6600103. Br J Cancer. 2002. PMID: 11875748 Free PMC article.

2

ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.

Magné N, Fischel JL, Dubreuil A, Formento P, Ciccolini J, Formento JL, Tiffon C, Renée N, Marchetti S, Etienne MC, Milano G. Magné N, et al. Among authors: fischel jl. Clin Cancer Res. 2003 Oct 15;9(13):4735-42. Clin Cancer Res. 2003. PMID: 14581344

3

Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab.

Formento P, Hannoun-Levi JM, Fischel JL, Magné N, Etienne-Grimaldi MC, Milano G. Formento P, et al. Among authors: fischel jl. Eur J Cancer. 2004 Dec;40(18):2837-44. doi: 10.1016/j.ejca.2004.07.033. Eur J Cancer. 2004. PMID: 15571968

4

Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft.

Formento P, Hannoun-Levi JM, Gérard F, Mazeau C, Fischel JL, Etienne-Grimaldi MC, Gugenheim J, Milano G. Formento P, et al. Among authors: fischel jl. Eur J Cancer. 2005 Jul;41(10):1467-73. doi: 10.1016/j.ejca.2005.03.021. Eur J Cancer. 2005. PMID: 15919200

5

Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation.

Bozec A, Formento P, Ciccolini J, Fanciullino R, Padovani L, Murraciole X, Fischel JL, Milano G. Bozec A, et al. Among authors: fischel jl. Mol Cancer Ther. 2005 Dec;4(12):1962-71. doi: 10.1158/1535-7163.MCT-05-0108. Mol Cancer Ther. 2005. PMID: 16373711

6

Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine.

Fischel JL, Ciccolini J, Formento P, Ferrero JM, Milano G. Fischel JL, et al. Anticancer Drugs. 2006 Aug;17(7):807-13. doi: 10.1097/01.cad.0000224444.23953.90. Anticancer Drugs. 2006. PMID: 16926630

7

Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil.

Magné N, Fischel JL, Tiffon C, Formento P, Dubreuil A, Renée N, Formento JL, Francoual M, Ciccolini J, Etienne MC, Milano G. Magné N, et al. Among authors: fischel jl. Br J Cancer. 2003 Aug 4;89(3):585-92. doi: 10.1038/sj.bjc.6601131. Br J Cancer. 2003. PMID: 12888834 Free PMC article.

8

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity.

Etienne MC, Ilc K, Formento JL, Laurent-Puig P, Formento P, Cheradame S, Fischel JL, Milano G. Etienne MC, et al. Among authors: fischel jl. Br J Cancer. 2004 Jan 26;90(2):526-34. doi: 10.1038/sj.bjc.6601523. Br J Cancer. 2004. PMID: 14735204 Free PMC article.

9

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors.

Fischel JL, Formento P, Milano G. Fischel JL, et al. Br J Cancer. 2005 Mar 28;92(6):1063-8. doi: 10.1038/sj.bjc.6602428. Br J Cancer. 2005. PMID: 15756277 Free PMC article.

10

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126.

Bozec A, Lassalle S, Gugenheim J, Fischel JL, Formento P, Hofman P, Milano G. Bozec A, et al. Among authors: fischel jl. Br J Cancer. 2006 Sep 18;95(6):722-8. doi: 10.1038/sj.bjc.6603308. Epub 2006 Aug 29. Br J Cancer. 2006. PMID: 16940984 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

78 results

Search Page

Filters